NIH-funded research R01 grant

Role of gut bacteria–driven Th17 cells in metabolic health

Official title: Role of intestinal commensal-induced Th17 cells and mucosal immunity in metabolic disease

Funded at Columbia University Health Sciences · NIH-11408423 · Data updated 2026-11-12

A study in mice explores how specific gut bacteria help protect against obesity- and diabetes-like changes by shaping a type of immune cell in the gut.

More Metabolic Disease research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionColumbia University Health Sciences
NIH-funded
Lab location1 site (New York, United States)
Project startApril 15, 2013
Project endJune 30, 2030
Funding year2026
Award (this year)$822,451
NIH project number5R01DK098378-12
Project IDNIH-11408423 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are individuals with metabolic syndrome or obesity who might benefit from therapies targeting gut immunity in the future.

Less likely to help

The findings may not directly benefit all individuals, especially those without metabolic or inflammatory gut issues until applied clinically.

What this research studies

We want to understand how intestinal immune cells called Th17 cells, influenced by gut bacteria, affect metabolism and fat tissue in the context of a high-fat, high-sugar diet. The project looks at how these immune cells regulate gut barrier function, inflammation, and lipid absorption, and whether they can prevent problems like insulin resistance. By using 3-D imaging and intestinal tissue models, researchers will dissect the pathways from the gut immune response to whole-body metabolic outcomes. This work could reveal new ways to target gut-immune interactions to improve metabolic health.

Why it matters

Potential benefit: If successful, this research could lead to new strategies that protect against obesity-related inflammation and metabolic diseases by modulating gut immunity.

How similar studies have gone: Previous work in animal models has shown that gut bacteria can influence metabolic health via Th17 cells, suggesting this is a promising area.

Where this research is happening

  • Columbia University Health Sciences
    New York, United States
    Active

Researchers

  • Principal investigator: Ivanov, Ivaylo Ivanov — Columbia University Health Sciences
  • Study coordinator: Ivanov, Ivaylo Ivanov

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.